Dermatomyositis – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Dermatomyositis – Pipeline Review, H1 2017’, provides an overview of the Dermatomyositis pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Dermatomyositis, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Dermatomyositis and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Dermatomyositis

– The report reviews pipeline therapeutics for Dermatomyositis by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Dermatomyositis therapeutics and enlists all their major and minor projects

– The report assesses Dermatomyositis therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Dermatomyositis

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Dermatomyositis

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Dermatomyositis pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Hope Pharmaceuticals Inc

Idera Pharmaceuticals Inc

KPI Therapeutics Inc

Marathon Pharmaceuticals LLC

MedImmune LLC

Neovacs SA

Novartis AG

Octapharma AG

Pfizer Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Dermatomyositis - Overview

Dermatomyositis - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Dermatomyositis - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Dermatomyositis - Companies Involved in Therapeutics Development

Eli Lilly and Company

F. Hoffmann-La Roche Ltd

Hope Pharmaceuticals Inc

Idera Pharmaceuticals Inc

KPI Therapeutics Inc

Marathon Pharmaceuticals LLC

MedImmune LLC

Neovacs SA

Novartis AG

Octapharma AG

Pfizer Inc

Dermatomyositis - Drug Profiles

anabasum - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

baricitinib - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

dalazatide - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

immune globulin (human) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IMO-8400 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MEDI-7734 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

MP-117 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

siponimod - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

sodium thiosulfate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tocilizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

tofacitinib citrate - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vaccine to Target IFN-Alpha for Metabolic Disorders, Immunology, Infectious Diseases and Musculoskeletal Disorders - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dermatomyositis - Dormant Projects

Dermatomyositis - Product Development Milestones

Featured News & Press Releases

May 17, 2017: FDA Grants Octapharma USA Orphan Drug Designation for Octagam 10% for the Treatment of Dermatomyositis

May 11, 2017: Corbus Pharmaceuticals Announces Last Subject Enrolled in Phase 2 Study of Anabasum for the Treatment of Skin-Predominant Dermatomyositis

May 04, 2017: Neovacs to present clinical development update on IFNalpha Kinoid in dermatomyosis

Mar 09, 2017: Neovacs to present IFNalpha Kinoid technology and its clinical outlooks at upcoming Keystone Symposia Conference

Feb 09, 2017: Neovacs Issued New Broad Patent in China for IFNa Kinoid

Nov 29, 2016: Corbus Pharmaceuticals Commences One-Year Open-Label Extension to its Ongoing Phase 2 Study of Resunab (JBT-101) for Skin-Predominant Dermatomyositis

Sep 28, 2016: Corbus Announces Data on Effects of Resunab (JBT-101) in a Clinical Research Model of Resolution of Inflammation

Nov 09, 2015: Idera Pharmaceuticals Announces Initiation of Phase 2 Clinical Trial of IMO-8400 in Patients with Dermatomyositis

Oct 13, 2015: Corbus Pharmaceuticals to Present at the 14th Annual BIO Investor Forum

Aug 06, 2015: Corbus Pharmaceuticals to Present at the Canaccord Genuity Growth Conference on August 13, 2015

Jul 13, 2015: Corbus Pharmaceuticals Announces Dosing of First Patient in Phase 2 Clinical Trial of Resunab for the Treatment of Dermatomyositis

Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis

Jun 16, 2015: Neovacs initiates clinical program in Dermatomyositis

Jun 05, 2015: Corbus Pharmaceuticals Expands Clinical Development of Resunab With a Phase 2 Trial for the Treatment of Rare Disease Dermatomyositis

May 13, 2015: Neovacs granted

1.8 million euros in research tax credit

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Dermatomyositis, H1 2017

Number of Products under Development by Companies, H1 2017

Products under Development by Companies, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Dermatomyositis – Pipeline by Eli Lilly and Company, H1 2017

Dermatomyositis – Pipeline by F. Hoffmann-La Roche Ltd, H1 2017

Dermatomyositis – Pipeline by Hope Pharmaceuticals Inc, H1 2017

Dermatomyositis – Pipeline by Idera Pharmaceuticals Inc, H1 2017

Dermatomyositis – Pipeline by KPI Therapeutics Inc, H1 2017

Dermatomyositis – Pipeline by Marathon Pharmaceuticals LLC, H1 2017

Dermatomyositis – Pipeline by MedImmune LLC, H1 2017

Dermatomyositis – Pipeline by Neovacs SA, H1 2017

Dermatomyositis – Pipeline by Novartis AG, H1 2017

Dermatomyositis – Pipeline by Octapharma AG, H1 2017

Dermatomyositis – Pipeline by Pfizer Inc, H1 2017

Dermatomyositis – Dormant Projects, H1 2017

List of Figures

List of Figures

Number of Products under Development for Dermatomyositis, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports